Abstracts tagged "Infection"

Abstract Number: 1374 • 2019 ACR/ARP Annual Meeting
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Huan Huang ³, Lawrence Chang ², Xin Wang ³ and Mark Genovese ⁴, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Plymouth Meeting, PA, ⁴Stanford University, Stanford, CA
Background/Purpose: Infections are common safety events monitored in RA patients.1 ACR guidelines limit the use of live vaccines in patients who are on biologic (b)DMARDs…
Abstract Number: 1515 • 2019 ACR/ARP Annual Meeting
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…
Abstract Number: 1805 • 2019 ACR/ARP Annual Meeting
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Marianne Kerski¹, Peter Boersma ², Eric Miller ³, Ashley Brenner ⁴, Genevieve Melton ⁵ and Anna Shmagel ⁶, ¹University of Minnesota Medical School, Minneapolis, MN, ²University of Minnesota School of Public Health, Minneapolis, ³University of Minnesota, Woodbury, MN, ⁴University of Minnesota Best Practices Integrated Informatics Core (BPIC), Minneapolis, MN, ⁵University of Minnesota Department of Surgery, Minneapolis, MN, ⁶University of Minnesota, Minneapolis, MN
Background/Purpose: Perioperative management of anti-rheumatic drugs in rheumatoid arthritis (RA) patients undergoing surgery remains controversial. Previous studies produced conflicting results, and data on non-orthopedic surgeries…
Abstract Number: 2095 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Kieran Murray¹, Candice Low ¹, Francis Young ¹, Anna O'Rourke ¹, Ian Callanan ², Eoin Feeney ¹ and Douglas Veale ³, ¹Saint Vincent's University Hospital, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin, Dublin, Ireland, ³EULAR Centre For Arthritis And Rheumatic Diseases and The Conway Institute, Dublin, Ireland
Background/Purpose: The ACR and CDC recommend influenza (“flu”) and 23-valent pneumococcal polysaccharide (PPSV23) vaccination for inflammatory arthritis (IA) patients on immunosuppression. This study aimed to:…
Abstract Number: 2103 • 2019 ACR/ARP Annual Meeting
Anti-TNF Therapy in Patients with HIV Infection
Joanna Marco¹ and Alison Bays ², ¹University of Washington, Seattle, WA, ²University of Washington Division of Rheumatology, Seattle, WA
Background/Purpose: Patients with Human Immunodeficiency Virus (HIV) infection may benefit from the use of anti-Tumor Necrosis Factor (TNF) therapy in the setting of inflammatory disease,…
Abstract Number: 2107 • 2019 ACR/ARP Annual Meeting
Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Eishi Uechi¹ and Kiyohide Fushimi ², ¹Tomishiro Central Hospital, Tomigusuku city, Okinawa, Japan, ²Tokyo Medical and Dental University Graduate School, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Pneumonia is a common cause of death not only in the general population but also in patients with rheumatoid arthritis (RA). In particular, patients…
Abstract Number: 2109 • 2019 ACR/ARP Annual Meeting
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Jaime Coral-Enriquez ¹, Mauricio Restrepo ², Gloria Vasquez ³, Carlos H Muñoz-Vahos ⁴, Daniel Jaramillo ⁵, Adriana Vanegas-García ⁴, Ruth Eraso ⁶, Johanna Hernández ⁷, Fabian Jaimes ⁸ and Luis Gonzalez², ¹Grupo de Reumatología, Universidad de Antioquia, Medellin, Colombia, ²Grupo de Reumatología, Division of Rheumatology, Department of Internal Medicine, School of Medicine Universidad de Antioquia, Medellín, Colombia, ³University of Antioquia, Medellin, Antioquia, Colombia, ⁴Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, ⁵Rheumatology unit, Hospital Universitario San Vicente Fundación, Medellin, Colombia, ⁶Grupo de Reumatología, Universidad de Antioquia; Pediatric rheumatology unit, Hospital Pablo Tobón Uribe, Medellin, Colombia, ⁷Division of Rheumatology, Pediatric Department, School of Medicine, Universidad de Antioquia, Medellín, Colombia, ⁸Department of Epidemiology, Hospital Universitario San Vicente Fundación, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia
Background/Purpose: Tuberculosis (TB) infection is an important cause of morbidity and mortality in systemic lupus erythematosus (SLE) patients, especially in developing countries. Previous studies have…
Abstract Number: 2122 • 2019 ACR/ARP Annual Meeting
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti ² and Augustine Manadan ³, ¹John H. Stroger Hospital of Cook County, Chicago, ²John H Stroger Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Septic arthritis is known to cause significant morbidity due to joint destruction and mortality if timely and adequate treatment is not given. In this study,…
Abstract Number: 942 • 2018 ACR/ARHP Annual Meeting
Risk of Serious Infections in Tocilizumab Versus TNF Inhibitor Initiators in Patients with RA: A Multi-Database Cohort Study
Ajinkya Pawar¹, Rishi J. Desai², Daniel Solomon¹, Sara Gale³, Min Bao⁴, Khaled Sarsour³, Sebastian Schneeweiss¹ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Genentech, South San Francisco, CA, ⁴Roche Innovation Center, New York, NY
Background/Purpose: While biologics are known to be associated with risk of serious infections, data on head-to-head comparison of different biologic drugs for the risk of…
Abstract Number: 2453 • 2018 ACR/ARHP Annual Meeting
Staphylococcus Aureus Carriage Rates Are High in Rheumatoid Arthritis Patients on Biologics
Susan M. Goodman¹, Bo Shopsin², Allina A. Nocon¹, Andy O. Miller³, Michael W. Henry³, Sarah E. Grond¹, Elianna Kaplowitz¹, Thomas P. Sculco⁴, Linda A. Russell³, Laura T. Donlin⁵, Mark P. Figgie⁴ and Peter K. Sculco⁴, ¹Hospital for Special Surgery, New York, NY, ²Medicine and Microbiology, New York University School of Medicine, New York, NY, ³Medicine, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Orthopaedic Surgery, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of surgical site infection than patients with osteoarthritis (OA). Disease modifying therapy is widely used…
Abstract Number: 1220 • 2018 ACR/ARHP Annual Meeting
The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis
Lior Nissim¹, Mary Louise Fowler², Robert Shmerling³, Sarah Lieber⁴, Mohammad Naffaa⁵ and Ziv Paz^4,5, ¹Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, ²Boston University School of Medicine, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Beth Israel Deaconess Medical Center, Boston, MA, ⁵Galilee Medical Center, Nahariya, Israel
Background/Purpose: Approximately 20,000 cases of septic arthritis (SA) occur in the United States each year with 2-10 cases per 100,000 person-years in the general population.…
Abstract Number: 2502 • 2018 ACR/ARHP Annual Meeting
Influence of the Treatment with Biologic Agents in the Viremia By the Endogenous Anelovirus Torque Teno Virus in Patients with Chronic Arthritis
Maria Martin-Lopez¹, Eliseo Albert², Esther Rodriguez-Almaraz³, Isidoro Gonzalez-Alvaro⁴, Mario Fernandez-Ruiz⁵, Jose M. Aguado⁵, David Navarro² and Jose L. Pablos⁶, ¹Rheumatology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain, ²Microbiology, Instituto de Investigación INCLIVA, Hospital Clínico, Valencia, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre. Unit of Infectious Diseases, Madrid, Spain, ⁶Rheumatology, Rheumatology Department, Hospital Universitario 12 de Octubre, Spain, Madrid, Spain
Background/Purpose: Torque teno virus (TTV) is an endogenous anellovirus that is highly prevalent in adult healthy subjects (up to 90%) without known pathogenicity. Increased replication…
Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Shubha Kollampare¹, C. Kent Kwoh^1,2, Wei-Hsuan Lo-Ciganic³, Lili Zhou^2,4, Erin L. Ashbeck² and Dominick Sudano¹, ¹Division of Rheumatology, Department of Medicine, The University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, Tucson, AZ, ³Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, TUCSON, AZ, ⁴College of Pharmacy, University of Arizona, Tucson, AZ
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…
Abstract Number: 2614 • 2018 ACR/ARHP Annual Meeting
The Effect of Secukinumab on the Immunogenicity of Influenza Vaccine in Patients with Psoriatic Arthritis
Ori Elkayam¹, Devy Zisman², Ilana Kaufman³, Uri Arad⁴, Mark Berman⁵, Victoria Furer⁶, Yael Lahat¹, Or Carmi¹, Amir Haddad⁷, Muna Elias⁷, Daphna Paran¹ and Michal Mandelbaum⁸, ¹Department of rheumatology, Tel Aviv medical center and the Sackler Faculty of medicine, Tel Aviv University, Tel Aviv, Israel, ²Technion, Rheumatology Unit Carmel Medical Center, Haifa, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel, ⁵Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, ⁷Rheumatology Unit Carmel Medical Center, Haifa, Israel, ⁸Sheba medical center, Ramat Gan, Israel
Background/Purpose: The humoral response to vaccination may be affected by the use of immunosuppressive drugs. The effect of secukinumab on the humoral response of vaccines…
Abstract Number: 1228 • 2018 ACR/ARHP Annual Meeting
Spine Immobilization and Neurological Complications in Vertebral Osteomyelitis: Results from a Multicenter Prospective Observational Study
Géraldine Bart¹, Guillaume Coiffier², Oriane Merot³, Emmanuel Hoppe⁴, Marion Couderc⁵, Denis Mulleman⁶, Gregoire Cormier⁷, Jean Marc Ziza⁸ and Benoit Le Goff¹, ¹Rheumatology, Nantes University Hospital, Nantes, France, ²Rheumatology, Rennes University Hospital, Rennes, France, ³rheumatology unit, Saint Nazaire Hospital, Saint Nazaire, France, ⁴Angers University Hospital, Angers, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Université François-Rabelais de Tours, CNRS 7292, Tours, France, ⁷Service de Rhumatologie, CHD de la Roche-Sur-Yon, La Roche-Sur-Yon, France, ⁸Medecine Interne-Rhumatologie, Groupe hospitalier Diaconesses-Croix-Saint-Simon, Paris, France
Background/Purpose: In a previous work, we showed that neurological complication can occur in up to 40% of patients with vertebral osteomyelitis (VO). Bed rest and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].